Abstract
Delayed diagnosis in patients with Churg–Strauss syndrome (CSS) is largely attributed to the variable and nonspecific presentation of the disease’s initial symptoms. The aim of the study was to evaluate the effect of delayed diagnosis on the course of CSS. We conducted a retrospective study of 30 CSS patients followed up in our department. In each patient, we assessed the delay in CSS diagnosis (the time when patients already fulfilled four out of six of the American College of Rheumatology criteria and the diagnosis was not yet established), the disease activity at the time of diagnosis, and organ involvement during CSS course. A median value of 2 weeks was chosen as the cutoff point after which the diagnosis was considered as delayed. Sixteen patients were diagnosed before (group 1) and 14 patients after this cutoff point (group 2). In group 2, we found a higher Birmingham Vasculitis Activity Score at the moment of diagnosis (20.4 vs 25.1, p < 0.05) and a more severe disease course, resulting in more frequent hospitalization rates (0.64 vs 2.26/year, p < 0.00001), higher corticosteroids dose requirements (5.87 vs 11.57 mg/day converted to methylprednisolone, p < 0.0001), and additional immunosuppressive therapy administration (56.2 vs 92.8 %, p < 0.05) to maintain disease remission. All six perinuclear pattern of antineutrophil cytoplasmic antibobodies (pANCA)-positive patients (20 %) were found in group 1. Concluding, the delay in diagnosis of CSS of more than 2 weeks was found to be associated with a disease course that was more severe. The presence of the pANCA antibodies may occasionally facilitate establishment of the diagnosis.
Similar content being viewed by others
References
Szczeklik W, Jakieła B, Adamek D, Musiał J (2011) Cutting edge issues in the Churg–Strauss syndrome. Clin Rev Allergy Immunol. doi:10.1007/s12016-011-8266-y
Churg J, Strauss L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27(2):277–301
Szczeklik W, Sokołowska B, Mastalerz L, Grzanka P, Górka J, Pacułt K, Miszalski-Jamka T, Soja J, Musiał J (2010) Pulmonary findings in Churg–Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol 29(10):1127–1134
Szczeklik W, Miszalski-Jamka T, Mastalerz L, Sokolowska B, Dropinski J, Banys R, Hor KN, Mazur W, Musial J (2011) Multimodality assessment of cardiac involvement in Churg–Strauss syndrome patients in clinical remission. Circ J 75(3):649–655
Dunogué B, Pagnoux C, Guillevin L (2011) Churg–Strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment. Semin Respir Crit Care Med 32(3):298–309. doi:10.1055/s-0031-1279826
Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, Bazan-Socha S, Szczeklik A, Musial J (2012) Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. Rheumatology (Oxford) 51(10):1887–1893
Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg–Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–1100
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68:1827–1832
Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG) (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90(1):19–27
Helbig G, Kyrcz-Krzemien S (2011) Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Pol Arch Med Wewn 121(1–2):44–52
Szczeklik W, Sokolowska BM, Zuk J, Mastalerz L, Szczeklik A, Musial J (2011) The course of asthma in Churg–Strauss syndrome. J Asthma 48(2):183–187
Szczeklik W, Sanak M, Mastalerz L, Sokołowska BM, Gielicz A, Soja J, Kumik J, Musiał J, Szczeklik A (2012) 12-Hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg–Strauss syndrome. Clin Exp Allergy 42:513–522
Bourgarit A, Le Toumelin P, Pagnoux C, Cohen P, Mahr A, Le Guern V, Mouthon L, Guillevin L; French Vasculitis Study Group (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg–Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84(5):323–330
Nazareth R, Mason JC (2011) Takayasu arteritis: severe consequences of delayed diagnosis. QJM 104(9):797–800
Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C (2011) Delayed diagnosis of Kawasaki disease: risk factors and outcome of treatment. Ann Trop Paediatr 31(2):109–114
Minich LL, Sleeper LA, Atz AM, McCrindle BW, Lu M, Colan SD, Printz BF, Klein GL, Sundel RP, Takahashi M, Li JS, Vetter VL, Newburger JW, Investigators PHN (2007) Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 120(6):e1434–e1440
Ezeonyeji AN, Borg FA, Dasgupta B (2011) Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 30(2):259–262
Ribi C, Cohen P, Pagnoux C, Mahr A, Arène JP, Lauque D, Puéchal X, Letellier P, Delaval P, Cordier JF, Guillevin L; French Vasculitis Study Group (2008) Treatment of Churg–Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58(2):586–594
Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P (1999) Churg–Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78:26.
Keogh KA, Specks U (2003) Churg–Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115(4):284–290
Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore) 63(2):65–81
Sinico RA, Bottero P (2009) Churg–Strauss angiitis. Best Pract Res Clin Rheumatol 23(3):355–366
Pagnoux C, Guilpain P, Guillevin L (2007) Churg–Strauss syndrome. Curr Opin Rheumatol 19(1):25–32
Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, Thibult N, Casassus P (1996) Prognostic factors in polyarteritis nodosa and Churg–Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75(1):17–28
Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G (2004) Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis 63(12):1649–1654
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sokołowska, B., Szczeklik, W., Mastalerz, L. et al. Effect of delayed diagnosis on disease course and management of Churg–Strauss syndrome: a retrospective study. Clin Rheumatol 32, 349–354 (2013). https://doi.org/10.1007/s10067-012-2127-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-012-2127-9